Peter Brown, DPhil, is a Pharmaceutical Consultant with 25 years of experience in the development of cancer therapeutics. Dr Brown was previously Vice President of Oncology Clinical Development at Teva Pharmaceutical Industries Ltd., and before that held the same position at Cephalon Inc. During his time at Cephalon, Dr. Brown led the clinical development program for bendamustine (TREANDA), completing two NDAs for the drug in 2008. Prior to joining Cephalon, Dr Brown was head of Oncology Clinical Research for British Biotech plc. Dr. Brown received his BSc degree in biochemistry from the University of London, and his DPhil in biochemistry from Oxford University. He spent 4 years as a Senior Staff Fellow at the National Cancer Institute, Bethesda, MD.